Journal
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY
Volume 8, Issue 6, Pages 373-383Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/1756283X15592586
Keywords
angiogenesis; gastric cancer; gastro-oesophageal cancer; ramucirumab; vascular endothelial growth factor; vascular endothelial growth factor receptor 2
Categories
Funding
- NIHR RM/ICR Biomedical Research Centre
Ask authors/readers for more resources
Ramucirumab, a fully humanized monoclonal antibody directed against vascular endothelial growth factor receptor 2, is the first targeted agent to have demonstrated an improvement in survival, as a single agent or in combination, in a molecularly unselected population in gastro-oesophageal cancer. Now that second-line treatment is routinely considered for patients with advanced gastro-oesophageal cancer, ramucirumab, with its favourable toxicity profile compared with cytotoxic treatment, provides a valuable additional treatment option.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available